Podcasts about Biotechnology

What happens when an entrepreneur turns their biggest fear—asking for money—into their secret weapon for success? In this episode of The Angel Next Door Podcast, host Marcia Dawood sits down with Maria Springer, founder of Capital Department, to discuss how founders can overcome fundraising anxiety and unlock new paths to capital.Maria's journey began in the social enterprise world of East Africa, where she quickly learned that mastering fundraising was vital to making an impact. Her hard-won expertise now powers Capital Department, a firm that has helped startups secure over $200 million, with a special emphasis on fueling growth through innovative community rounds and crowdfunding.This episode is essential listening for startup founders and investors alike. Maria and Marcia dive into how narrative and organization are key to successful fundraising, the evolving landscape of crowdfunding, and why engaging your community is more powerful than ever. If you want practical fundraising advice and insider stories—like how Pirouette outperformed Substack with a record-setting raise—this conversation is packed with takeaways you won't want to miss. To get the latest from Maria Springer, you can follow her below!https://www.linkedin.com/in/mariaspringer/https://www.capitaldept.com/ Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

Synopsis: What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents. Biography: Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company's mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases. Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company's Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris' legal and intellectual property functions, including licensing, corporate governance, and management of the company's global patent portfolio. Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP. Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master's in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

The gaps in women's healthcare can be addressed by the Gen Z listeners of this podcast! A professional polymath, Michal Morrison has spent her career bridging the past and present, business and impact. Holding degrees in History and English and a graduate degree in Theology, her academic foundation launched her into 10 years in archaeological and historical research across the Middle East and Mediterranean. She has worked for universities, environmental agencies, and a royal family on heritage protection projects and field research in Greece, Italy, the United Arab Emirates, Turkey, Ireland, and the Americas. A life-changing accident served as a catalyst for a significant career change, and in 2020 Michal founded her eponymous skincare company, Michal Morrison Inc., where she is proud to partner with global leaders from the fields of biotechnology, longevity, and beauty. Michal Morrison is an award-winning biomimetic skincare brand featuring a patented biotech breakthrough based in 25 years of research in regenerative medicine and stem cell science. As a survivor of a Traumatic Brain Injury, Michal believes that businesses should be catalysts for social change. She is dedicated to not only driving scientific innovation in the beauty industry, but to building a sustainably-minded brand that prioritizes accessibility. She launched her brand's social impact initiative, where they have partnered with One Mind, The Trevor Project, and the COPE Program in support of health equity within Indigenous communities. In episode 587 of the Fraternity Foodie Podcast, we find out why Michal chose Texas A&M for her undergraduate experience, how her curiosity evolved into archaeological work, what are the unexpected lessons she learned from her time in international heritage work, how a Traumatic Brain Injury changed her career path, how to adapt with purpose, why she took the leap into biotech and beauty, what has been the most rewarding part of being a woman entrepreneur, how her company integrates purpose with profit, gaps in women's healthcare that Gen Z can address, and common fears or hurdles that young entrepreneurs face. Two books Michal recommended: "Raise Capital On Your Own Terms" and "Leap Frog". If they students are experiencing anxiety around life decisions, pick up "Don't Believe Everything You Think". It's been invaluable to Michal in learning how to have more control over her own occasional existential spirals and managing the 'what ifs' of life.

Êtes-vous prêt à découvrir comment les plantes tinctoriales peuvent transformer notre perception de la couleur et de l'art ? Dans cet épisode captivant d'ArtEcoVert, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome passionnée par la couleur végétale. Elle nous emmène dans un voyage fascinant à travers l'univers des colorants végétaux, en mettant en lumière le magazine numéro 3 Couleur Végétale, qui célèbre le savoir-faire artisanal et la transmission des connaissances autour de la teinture végétale.Pauline nous explique pourquoi il est crucial pour les artistes et designers d'explorer la richesse des pigments végétaux, en partageant des études de cas sur l'utilisation de la teinture à base de plantes dans la restauration d'œuvres d'art. Saviez-vous que des couleurs comme l'indigo et la garance ont des histoires aussi riches que les œuvres qu'elles colorent ? Au cours de cet épisode, nous découvrons également les différentes filières émergentes qui se développent autour de la couleur végétale, ainsi que des témoignages d'artistes et d'experts passionnés.En outre, cet épisode explore des projets innovants de tourisme tinctorial et des initiatives visant à préserver le patrimoine culturel lié à ces pratiques ancestrales. Pauline invite les auditeurs à s'engager activement dans des projets autour de la couleur végétale et à soutenir le podcast ArtEcoVert en se connectant avec des acteurs locaux. Vous découvrirez des ressources précieuses pour approfondir vos connaissances sur les fibres naturelles, les tanins, et les nuances de la teinture.Ne manquez pas cette occasion d'élargir votre horizon sur le monde des plantes tinctoriales et de la couleur ! Comme le dit si bien Pauline, "la couleur végétale est un pont entre la nature et l'art". Plongez dans cet épisode inspirant et laissez-vous emporter par la magie des colorants biosourcés. Belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Latt Mansor explores the multifaceted role of ketones, particularly their influence on brain health, fertility, memory, and focus. The re-release of an episode from 2023 delves into their impact on serotonin receptors, blood glucose regulation, and weight management. Mansor also highlights the potential therapeutic benefits of ketones for conditions such as sleep disturbances, infertility, depression, and Alzheimer's. If you want a balanced approach to health discussions, where scientific understanding encourages expanded knowledge and experience rather than limitations, this is the episode for you. To view full show notes, more information on our guests, resources mentioned in the episode, discount codes, transcripts, and more, visit https://drmindypelz.com/ep296 Dr. Latt Mansor holds a Ph.D. in Physiology, Anatomy and Genetics from the University of Oxford, where his research focused on the metabolism of type 2 diabetic heart in hypoxia. He also holds an M.A. (Columbia University) and a B.Sc. (Hons) (University of Nottingham) in Biotechnology. He is a world expert in physiology and metabolism and consults with elite sports, military, clinical and research organizations. Check out our fasting membership at resetacademy.drmindypelz.com. Please note our medical disclaimer.

Qu'est-ce qui se cache derrière la magie des couleurs végétales ? Dans cet épisode captivant d'ArtEcoVert, nous plongeons dans l'univers fascinant des plantes tinctoriales avec notre invitée exceptionnelle, Aline Perdereau, agricultrice passionnée de Bretagne. Aline, qui a fait le saut audacieux du droit public vers l'agriculture, nous partage son expérience unique de culture de la persiquaire indigo, une plante essentielle pour la teinture naturelle. Au fil de notre conversation, Aline nous dévoile les secrets des techniques de culture, d'extraction et de séchage qu'elle utilise pour produire des colorants végétaux d'une beauté exceptionnelle. Elle nous explique comment l'indigo et d'autres pigments végétaux peuvent transformer nos textiles et nos décorations tout en respectant notre précieuse planète. Les enjeux écologiques et économiques de l'agriculture durable sont également au cœur de nos échanges, soulignant l'importance de la biodiversité dans la préservation de notre environnement. « La couleur végétale, c'est bien plus qu'une simple teinture, c'est une manière de reconnecter avec la nature », déclare Aline. Cette citation résume parfaitement l'essence de notre discussion, où nous explorons les nuances infinies que les plantes peuvent offrir. Nous parlerons également des tanins et de la richesse des fibres naturelles qui composent notre quotidien. Dans cet épisode, nous mettons en lumière l'impact positif de la teinture végétale sur la santé humaine et la planète. Les pratiques respectueuses de l'environnement qu'Aline intègre dans son travail sont une véritable source d'inspiration pour tous ceux qui souhaitent embrasser une agriculture tinctoriale durable. Si vous êtes passionné par les jardins, les biotechnologies, ou simplement curieux d'en savoir plus sur le monde des plantes tinctoriales, cet épisode est fait pour vous ! Rejoignez-nous pour découvrir comment la couleur végétale peut transformer notre approche de la teinture et de l'agriculture. Pour en savoir plus sur Aline et son travail, n'hésitez pas à consulter les liens utiles dans la description. Belle écoute et à très bientôt dans ArtEcoVert, la voix de la couleur végétale et des plantes tinctoriales !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Go to https://cozyearth.com and use code HUMANHR for 40% off their best-selling sheets, pajamas, towels, and more. And if you get a post-purchase survey? Let them know you heard about Cozy Earth right here.In this episode, Traci Chernoff interviews Steven Swan, CEO of the Swan Group Executive Search Firm, discussing the evolving landscape of recruiting, particularly the influence of AI. They explore the balance between speed and quality in recruitment, the importance of human connection, and the advantages of external recruiting. Steven shares insights on crafting effective resumes and the purpose behind his podcast, emphasizing the need for emotional intelligence in decision-making during job changes.Chapters00:00 Introduction to Steve Swan and His Journey03:04 The Impact of AI on Recruiting06:02 Quality vs. Speed in Recruitment09:06 The Role of Human Connection in Recruitment12:00 The Advantages of External Recruiting15:11 Crafting Effective Resumes and LinkedIn Profiles17:56 The Purpose Behind the Podcast20:58 Advice for Aspiring Recruiters23:59 Navigating Job Changes and Emotional IntelligenceWe hope you enjoyed this episode with Steven Swan. If you found our discussion insightful, we'd like you to take a moment to rate our podcast. Your feedback helps us grow and reach more listeners who are passionate about these topics. You can also leave a review and tell us what you loved or what you'd like to hear more of - we're all ears!Don't forget to rate, review, and subscribe! Plus, leave a comment if you're catching this episode on Spotify or YouTube.About Our Guest: Steve Swan stands at the helm of The Swan Group Executive Search Firm as its CEO and Principal, carving a niche in the Pharma/Biotech industries with a keen focus on IT. His fervor for industry insights and a knack for bridging the gap between top professionals and industry demands have been instrumental in elevating organizations and propelling careers forward.Steve helms the popular podcast “Biotech Bytes.” A show that offers a stage for dialogue with IT luminaries in Biotechnology and Pharmaceuticals. Each episode delves into the minds of industry trailblazers, unpacking best practices and strategies that shape the life sciences realm. Steve's academic background in Psychology has helped him to understand both parties' deeper needs and motivations which is paramount to delivering candidates who become long-term  assets to the company. At the core of The Swan Group's philosophy is the ability to discern and fulfill what success means for both candidates and clients. Outside of work, Steve, once an avid mountain bike racer, has reignited his passion for cycling and aspires to traverse the U.S. on  two wheels. He lives in New Jersey with his wife and two daughters.Connect with Steven Swan here:LinkedIn: https://www.linkedin.com/in/swangroup/ Website: https://swangroup.net/ Connect with Traci here: ⁠https://linktr.ee/HRTraci⁠Disclaimer: Thoughts, opinions, and statements made on this podcast are not a reflection of the thoughts, opinions, and statements of the Company by whom Traci Chernoff is actively employed.Please note that this episode may contain paid endorsements and advertisements for products or services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.

Skeletal muscle is one of the most abundant tissues in the human body, representing approximately 40% of body weight. Under certain circumstances, skeletal muscle can be regenerated through satellite cells, a reservoir of quiescent muscle stem cells, that can be activated with injury or in certain diseases and give rise to newly formed multi-nucleated myotubes and myofibers. However, the regenerative potential of muscle is diminished or is completely absent in the course of normal aging, certain diseases, and space travel. For example, time spent in microgravity can have a profound impact on human physiology, especially the muscular system, as astronauts lose up to 20% of their lean muscle mass and up to half of their strength.  The identification of countermeasures against the effects of muscle regeneration, including microgravity, is an increasing priority for an aging population and continued space travel. Experiments in microgravity, conducted on the International Space Station, offer a unique opportunity to understand muscle regeneration and the effects of microgravity. Our guests today will discuss muscle regeneration, their muscle-on-a-chip platform that mimics salient aspects of impaired muscle regeneration, and the feasibility of drug screening in microgravity.GuestsNgan Huang, PhD, Department of Cardiothoracic Surgery, Stanford University, USASoochi Kim, PhD, Department of Biotechnology and Bioinformatics, Korea University, KoreaHostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting ContentPaper link:  Skeletal muscle-on-a-chip in microgravity as a platform for regeneration modeling and drug screeningAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Senior Marketing ManagerJack Mosher, Scientific DirectorHunter Reed, Senior Marketing Coordinator

We love to hear from our listeners. Send us a message. This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies. Amber talks about FSHD, a progressive muscular dystrophy, how the company raised $68 million in Series B funding despite challenging market conditions, her partnership with Springbok Analytics for AI analysis of MRI images, working with a CDMO to manufacture a new treatment modality, and navigating the FDA during a time of disruption. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Savez-vous que les plantes tinctoriales peuvent transformer non seulement notre manière de percevoir la couleur, mais aussi notre rapport à la nature et à l'agriculture ? Dans cet épisode captivant du podcast ArtEcoVert, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome passionnée par la teinture végétale et les plantes tinctoriales. Elle nous plonge dans l'univers fascinant des pigments végétaux, tels que l'indigo et la garance, et nous fait découvrir leur richesse et leur importance dans notre écosystème. Au cœur de cet échange, Géraldine Goyat, fondatrice de l'association Antémis, partage son aventure inspirante de la création de cette initiative en 2023. Antémis a pour mission de réintroduire des plantes tinctoriales dans les Hauts-de-France, notamment dans la région des Sept-Vallées. Géraldine aborde les défis contemporains tels que la désertification rurale et le vieillissement de la population, tout en expliquant comment leur projet s'inscrit dans une démarche de durabilité, d'insertion sociale et de valorisation du patrimoine local. « La couleur végétale est une passerelle entre l'art et la nature », souligne Géraldine, et cet épisode explore comment cette vision se traduit par des collaborations innovantes avec des établissements d'enseignement supérieur. Ces partenariats visent à développer des applications artistiques et économiques autour des plantes tinctoriales, tout en réhabilitant des sites historiques et des jardins médiévaux. Nous discuterons également des biotechnologies et des méthodes pour construire un modèle économique viable et durable autour de la teinture à base de fibres naturelles et de colorants végétaux. Les tanins, les nuances et les propriétés des pigments végétaux seront également au rendez-vous, offrant un aperçu complet de l'univers de la couleur végétale. Ne manquez pas cette occasion de découvrir comment l'engagement de passionnés comme Géraldine et Pauline peut redéfinir notre rapport à la nature et à l'art. Pour en savoir plus sur ces initiatives inspirantes et les défis à relever, écoutez cet épisode enrichissant d'ArtEcoVert. Pour des liens utiles et des ressources supplémentaires sur la teinture végétale, les plantes tinctoriales et bien plus encore, restez à l'écoute. Belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Et si la teinture végétale devenait la norme d'ici 2050 ? Dans cet épisode captivant d'ArtEcoVert, Pauline Leroux et Emilie Roulland nous plongent dans l'univers fascinant des plantes tinctoriales et des innovations qui pourraient transformer notre approche de la couleur végétale. À travers une discussion riche et éclairante, elles explorent les grandes tendances sociétales qui façonneront l'avenir de la teinture végétale, tout en mettant en lumière l'importance cruciale de choix audacieux dans les domaines politique, scientifique et économique. Emilie, experte en biotechnologies, nous présente cinq futurs potentiels pour la teinture végétale, où des concepts tels que la biologie des couleurs intelligentes et la circularité prennent tout leur sens. Les thèmes abordés incluent la valorisation des savoir-faire ancestraux et l'importance de la transparence et de la traçabilité dans le secteur. Imaginez un monde où les pigments végétaux, issus de la fermentation, remplacent les teintures synthétiques, et où des couleurs comme l'indigo et la garance retrouvent leur place dans nos jardins et nos textiles. Les intervenantes soulignent également le rôle essentiel des fibres naturelles et des tanins, qui contribuent à une approche plus durable et respectueuse de l'environnement. La conversation se veut optimiste, car de nombreuses initiatives sont déjà en cours, bien qu'elles ne soient pas encore largement adoptées. En effet, la prise de conscience collective est primordiale pour favoriser des pratiques durables et innovantes dans le domaine de l'agriculture tinctoriale. En écoutant cet épisode, vous découvrirez comment la couleur végétale peut être synonyme de soin et de respect de notre planète. Avec des discussions techniques et des partages d'expériences, Pauline et Emilie vous invitent à réfléchir aux nuances de la teinture végétale et à l'impact qu'elle pourrait avoir sur notre avenir. Alors, êtes-vous prêt à plonger dans l'univers coloré et engagé de la teinture végétale ? Pour en savoir plus sur les sujets abordés, n'hésitez pas à consulter les liens utiles que nous avons préparés pour vous. Belle écoute ! ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

On the latest episode of The Monthly Grind with the National Corn Growers Association, we discuss trade, tariffs and the impact on the rural economy with Nancy Martinez, Director, Public Policy, Trade and Biotechnology with NCGA and Jolene Riessen, Chair of the Iowa Corn Growers Association who also serves on NCGA's Trade, Transportation, and Animal Action Team. 

On Wednesday's AOA, we start the show with a look at the markets in Segment One with DuWayne Bosse from Bolt Marketing. In Segment Two, it's the latest episode of The Monthly Grind with the National Corn Growers Association. We discuss trade and tariffs with Nancy Martinez, Director, Public Policy, Trade and Biotechnology with NCGA and Jolene Riessen, Chair of the Iowa Corn Growers Association who also serves on NCGA's Trade, Transportation, and Animal Action Team. In Segment Three, we talk One Big, Beautiful Bill along with MAHA, trade and more as Kam Quarles, CEO at the National Potato Council joins the show. Then in Segment Four, we discuss livestock news and issues with Carrie Stadheim, Editor at Tri-State Livestock News.

What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

My fellow pro-growth/progress/abundance Up Wingers,Once-science-fiction advancements like AI, gene editing, and advanced biotechnology have finally arrived, and they're here to stay. These technologies have seemingly set us on a course towards a brand new future for humanity, one we can hardly even picture today. But progress doesn't happen overnight, and it isn't the result of any one breakthrough.As Jamie Metzl explains in his new book, Superconvergence: How the Genetics, Biotech, and AI Revolutions will Transform our Lives, Work, and World, tech innovations work alongside and because of one another, bringing about the future right under our noses.Today on Faster, Please! — The Podcast, I chat with Metzl about how humans have been radically reshaping the world around them since their very beginning, and what the latest and most disruptive technologies mean for the not-too-distant future.Metzl is a senior fellow of the Atlantic Council and a faculty member of NextMed Health. He has previously held a series of positions in the US government, and was appointed to the World Health Organization's advisory committee on human genome editing in 2019. He is the author of several books, including two sci-fi thrillers and his international bestseller, Hacking Darwin.In This Episode* Unstoppable and unpredictable (1:54)* Normalizing the extraordinary (9:46)* Engineering intelligence (13:53)* Distrust of disruption (19:44)* Risk tolerance (24:08)* What is a “newnimal”? (13:11)* Inspired by curiosity (33:42)Below is a lightly edited transcript of our conversation. Unstoppable and unpredictable (1:54)The name of the game for all of this . . . is to ask “What are the things that we can do to increase the odds of a more positive story and decrease the odds of a more negative story?”Pethokoukis: Are you telling a story of unstoppable technological momentum or are you telling a story kind of like A Christmas Carol, of a future that could be if we do X, Y, and Z, but no guarantees?Metzl: The future of technological progress is like the past: It is unstoppable, but that doesn't mean it's predetermined. The path that we have gone over the last 12,000 years, from the domestication of crops to building our civilizations, languages, industrialization — it's a bad metaphor now, but — this train is accelerating. It's moving faster and faster, so that's not up for grabs. It is not up for grabs whether we are going to have the capacities to engineer novel intelligence and re-engineer life — we are doing both of those things now in the early days.What is up for grabs is how these revolutions will play out, and there are better and worse scenarios that we can imagine. The name of the game for all of this, the reason why I do the work that I do, why I write the books that I write, is to ask “What are the things that we can do to increase the odds of a more positive story and decrease the odds of a more negative story?”Progress has been sort of unstoppable for all that time, though, of course, fits and starts and periods of stagnation —— But when you look back at those fits and starts — the size of the Black Plague or World War II, or wiping out Berlin, and Dresden, and Tokyo, and Hiroshima, and Nagasaki — in spite of all of those things, it's one-directional. Our technologies have gotten more powerful. We've developed more capacities, greater ability to manipulate the world around us, so there will be fits and starts but, as I said, this train is moving. That's why these conversations are so important, because there's so much that we can, and I believe must, do now.There's a widely held opinion that progress over the past 50 years has been slower than people might have expected in the late 1960s, but we seem to have some technologies now for which the momentum seems pretty unstoppable.Of course, a lot of people thought, after ChatGPT came out, that superintelligence would happen within six months. That didn't happen. After CRISPR arrived, I'm sure there were lots of people who expected miracle cures right away.What makes you think that these technologies will look a lot different, and our world will look a lot different than they do right now by decade's end?They certainly will look a lot different, but there's also a lot of hype around these technologies. You use the word “superintelligence,” which is probably a good word. I don't like the words “artificial intelligence,” and I have a six-letter framing for what I believe about AGI — artificial general intelligence — and that is: AGI is BS. We have no idea what human intelligence is, if we define our own intelligence so narrowly that it's just this very narrow form of thinking and then we say, “Wow, we have these machines that are mining the entirety of digitized human cultural history, and wow, they're so brilliant, they can write poems — poems in languages that our ancestors have invented based on the work of humans.” So we humans need to be very careful not to belittle ourselves.But we're already seeing, across the board, if you say, “Is CRISPR on its own going to fundamentally transform all of life?” The answer to that is absolutely no. My last book was about genetic engineering. If genetic engineering is a pie, genome editing is a slice and CRISPR is just a tiny little sliver of that slice. But the reason why my new book is called Superconvergence, the entire thesis is that all of these technologies inspire, and influence, and are embedded in each other. We had the agricultural revolution 12,000 years ago, as I mentioned. That's what led to these other innovations like civilization, like writing, and then the ancient writing codes are the foundation of computer codes which underpin our machine learning and AI systems that are allowing us to unlock secrets of the natural world.People are imagining that AI equals ChatGPT, but that's really not the case (AI equals ChatGPT like electricity equals the power station). The story of AI is empowering us to do all of these other things. As a general-purpose technology, already AI is developing the capacity to help us just do basic things faster. Computer coding is the archetypal example of that. Over the last couple of years, the speed of coding has improved by about 50 percent for the most advanced human coders, and as we code, our coding algorithms are learning about the process of coding. We're just laying a foundation for all of these other things.That's what I call “boring AI.” People are imagining exciting AI, like there's a magic AI button and you just press it and AI cures cancer. That's not how it's going to work. Boring AI is going to be embedded in human resource management. It's going to be embedded just giving us a lot of capabilities to do things better, faster than we've done them before. It doesn't mean that AIs are going to replace us. There are a lot of things that humans do that machines can just do better than we are. That's why most of us aren't doing hunting, or gathering, or farming, because we developed machines and other technologies to feed us with much less human labor input, and we have used that reallocation of our time and energy to write books and invent other things. That's going to happen here.The name of the game for us humans, there's two things: One is figuring out what does it mean to be a great human and over-index on that, and two, lay the foundation so that these multiple overlapping revolutions, as they play out in multiple fields, can be governed wisely. That is the name of the game. So when people say, “Is it going to change our lives?” I think people are thinking of it in the wrong way. This shirt that I'm wearing, this same shirt five years from now, you'll say, “Well, is there AI in your shirt?” — because it doesn't look like AI — and what I'm going to say is “Yes, in the manufacturing of this thread, in the management of the supply chain, in figuring out who gets to go on vacation, when, in the company that's making these buttons.” It's all these little things. People will just call it progress. People are imagining magic AI, all of these interwoven technologies will just feel like accelerating progress, and that will just feel like life.Normalizing the extraordinary (9:46)20, 30 years ago we didn't have the internet. I think things get so normalized that this just feels like life.What you're describing is a technology that economists would call a general-purpose technology. It's a technology embedded in everything, it's everywhere in the economy, much as electricity.What you call “boring AI,” the way I think about it is: I was just reading a Wall Street Journal story about Applebee's talking about using AI for more efficient customer loyalty programs, and they would use machine vision to look at their tables to see if they were cleaned well enough between customers. That, to people, probably doesn't seem particularly science-fictional. It doesn't seem world-changing. Of course, faster growth and a more productive economy is built on those little things, but I guess I would still call those “boring AI.”What to me definitely is not boring AI is the sort of combinatorial aspect that you're talking about where you're talking about AI helping the scientific discovery process and then interweaving with other technologies in kind of the classic Paul Romer combinatorial way.I think a lot of people, if they look back at their lives 20 or 30 years ago, they would say, “Okay, more screen time, but probably pretty much the same.”I don't think they would say that. 20, 30 years ago we didn't have the internet. I think things get so normalized that this just feels like life. If you had told ourselves 30 years ago, “You're going to have access to all the world's knowledge in your pocket.” You and I are — based on appearances, although you look so youthful — roughly the same age, so you probably remember, “Hurry, it's long distance! Run down the stairs!”We live in this radical science-fiction world that has been normalized, and even the things that you are mentioning, if you see open up your newsfeed and you see that there's this been incredible innovation in cancer care, and whether it's gene therapy, or autoimmune stuff, or whatever, you're not thinking, “Oh, that was AI that did that,” because you read the thing and it's like “These researchers at University of X,” but it is AI, it is electricity, it is agriculture. It's because our ancestors learned how to plant seeds and grow plants where you're stationed and not have to do hunting and gathering that you have had this innovation that is keeping your grandmother alive for another 10 years.What you're describing is what I call “magical AI,” and that's not how it works. Some of the stuff is magical: the Jetsons stuff, and self-driving cars, these things that are just autopilot airplanes, we live in a world of magical science fiction and then whenever something shows up, we think, “Oh yeah, no big deal.” We had ChatGPT, now ChatGPT, no big deal?If you had taken your grandparents, your parents, and just said, “Hey, I'm going to put you behind a screen. You're going to have a conversation with something, with a voice, and you're going to do it for five hours,” and let's say they'd never heard of computers and it was all this pleasant voice. In the end they said, “You just had a five-hour conversation with a non-human, and it told you about everything and all of human history, and it wrote poems, and it gave you a recipe for kale mush or whatever you're eating,” you'd say, “Wow!” I think that we are living in that sci-fi world. It's going to get faster, but every innovation, we're not going to say, “Oh, AI did that.” We're just going to say, “Oh, that happened.”Engineering intelligence (13:53)I don't like the word “artificial intelligence” because artificial intelligence means “artificial human intelligence.” This is machine intelligence, which is inspired by the products of human intelligence, but it's a different form of intelligence . . .I sometimes feel in my own writing, and as I peruse the media, like I read a lot more about AI, the digital economy, information technology, and I feel like I certainly write much less about genetic engineering, biotechnology, which obviously is a key theme in your book. What am I missing right now that's happening that may seem normal five years from now, 10 years, but if I were to read about it now or understand it now, I'd think, “Well, that is kind of amazing.”My answer to that is kind of everything. As I said before, we are at the very beginning of this new era of life on earth where one species, among the billions that have ever lived, suddenly has the increasing ability to engineer novel intelligence and re-engineer life.We have evolved by the Darwinian processes of random mutation and natural selection, and we are beginning a new phase of life, a new Cambrian Revolution, where we are creating, certainly with this novel intelligence that we are birthing — I don't like the word “artificial intelligence” because artificial intelligence means “artificial human intelligence.” This is machine intelligence, which is inspired by the products of human intelligence, but it's a different form of intelligence, just like dolphin intelligence is a different form of intelligence than human intelligence, although we are related because of our common mammalian route. That's what's happening here, and our brain function is roughly the same as it's been, certainly at least for tens of thousands of years, but the AI machine intelligence is getting smarter, and we're just experiencing it.It's become so normalized that you can even ask that question. We live in a world where we have these AI systems that are just doing more and cooler stuff every day: driving cars, you talked about discoveries, we have self-driving laboratories that are increasingly autonomous. We have machines that are increasingly writing their own code. We live in a world where machine intelligence has been boxed in these kinds of places like computers, but very soon it's coming out into the world. The AI revolution, and machine-learning revolution, and the robotics revolution are going to be intersecting relatively soon in meaningful ways.AI has advanced more quickly than robotics because it hasn't had to navigate the real world like we have. That's why I'm always so mindful of not denigrating who we are and what we stand for. Four billion years of evolution is a long time. We've learned a lot along the way, so it's going to be hard to put the AI and have it out functioning in the world, interacting in this world that we have largely, but not exclusively, created.But that's all what's coming. Some specific things: 30 years from now, my guess is many people who are listening to this podcast will be fornicating regularly with robots, and it'll be totally normal and comfortable.. . . I think some people are going to be put off by that.Yeah, some people will be put off and some people will be turned on. All I'm saying is it's going to be a mix of different —Jamie, what I would like to do is be 90 years old and be able to still take long walks, be sharp, not have my knee screaming at me. That's what I would like. Can I expect that?I think this can help, but you have to decide how to behave with your personalized robot.That's what I want. I'm looking for the achievement of human suffering. Will there be a world of less human suffering?We live in that world of less human suffering! If you just look at any metric of anything, this is the best time to be alive, and it's getting better and better. . . We're living longer, we're living healthier, we're better educated, we're more informed, we have access to more and better food. This is by far the best time to be alive, and if we don't massively screw it up, and frankly, even if we do, to a certain extent, it'll continue to get better.I write about this in Superconvergence, we're moving in healthcare from our world of generalized healthcare based on population averages to precision healthcare, to predictive and preventive. In education, some of us, like myself, you have had access to great education, but not everybody has that. We're going to have access to fantastic education, personalized education everywhere for students based on their own styles of learning, and capacities, and native languages. This is a wonderful, exciting time.We're going to get all of those things that we can hope for and we're going to get a lot of things that we can't even imagine. And there are going to be very real potential dangers, and if we want to have the good story, as I keep saying, and not have the bad story, now is the time where we need to start making the real investments.Distrust of disruption (19:44)Your job is the disruption of this thing that's come before. . . stopping the advance of progress is just not one of our options.I think some people would, when they hear about all these changes, they'd think what you're telling them is “the bad story.”I just talked about fornicating with robots, it's the bad story?Yeah, some people might find that bad story. But listen, we live at an age where people have recoiled against the disruption of trade, for instance. People are very allergic to the idea of economic disruption. I think about all the debate we had over stem cell therapy back in the early 2000s, 2002. There certainly is going to be a certain contingent that, what they're going to hear what you're saying is: you're going to change what it means to be a human. You're going to change what it means to have a job. I don't know if I want all this. I'm not asking for all this.And we've seen where that pushback has greatly changed, for instance, how we trade with other nations. Are you concerned that that pushback could create regulatory or legislative obstacles to the kind of future you're talking about?All of those things, and some of that pushback, frankly, is healthy. These are fundamental changes, but those people who are pushing back are benchmarking their own lives to the world that they were born into and, in most cases, without recognizing how radical those lives already are, if the people you're talking about are hunter-gatherers in some remote place who've not gone through domestication of agriculture, and industrialization, and all of these kinds of things, that's like, wow, you're going from being this little hunter-gatherer tribe in the middle of Atlantis and all of a sudden you're going to be in a world of gene therapy and shifting trading patterns.But the people who are saying, “Well, my job as a computer programmer, as a whatever, is going to get disrupted,” your job is the disruption. Your job is the disruption of this thing that's come before. As I said at the start of our conversation, stopping the advance of progress is just not one of our options.We could do it, and societies have done it before, and they've lost their economies, they've lost their vitality. Just go to Europe, Europe is having this crisis now because for decades they saw their economy and their society, frankly, as a museum to the past where they didn't want to change, they didn't want to think about the implications of new technologies and new trends. It's why I am just back from Italy. It's wonderful, I love visiting these little farms where they're milking the goats like they've done for centuries and making cheese they've made for centuries, but their economies are shrinking with incredible rapidity where ours and the Chinese are growing.Everybody wants to hold onto the thing that they know. It's a very natural thing, and I'm not saying we should disregard those views, but the societies that have clung too tightly to the way things were tend to lose their vitality and, ultimately, their freedom. That's what you see in the war with Russia and Ukraine. Let's just say there are people in Ukraine who said, “Let's not embrace new disruptive technologies.” Their country would disappear.We live in a competitive world where you can opt out like Europe opted out solely because they lived under the US security umbrella. And now that President Trump is threatening the withdrawal of that security umbrella, Europe is being forced to race not into the future, but to race into the present.Risk tolerance (24:08). . . experts, scientists, even governments don't have any more authority to make these decisions about the future of our species than everybody else.I certainly understand that sort of analogy, and compared to Europe, we look like a far more risk-embracing kind of society. Yet I wonder how resilient that attitude — because obviously I would've said the same thing maybe in 1968 about the United States, and yet a decade later we stopped building nuclear reactors — I wonder how resilient we are to anything going wrong, like something going on with an AI system where somebody dies. Or something that looks like a cure that kills someone. Or even, there seems to be this nuclear power revival, how resilient would that be to any kind of accident? How resilient do you think are we right now to the inevitable bumps along the way?It depends on who you mean by “we.” Let's just say “we” means America because a lot of these dawns aren't the first ones. You talked about gene therapy. This is the second dawn of gene therapy. The first dawn came crashing into a halt in 1999 when a young man at the University of Pennsylvania died as a result of an error carried out by the treating physicians using what had seemed like a revolutionary gene therapy. It's the second dawn of AI after there was a lot of disappointment. There will be accidents . . .Let's just say, hypothetically, there's an accident . . . some kind of self-driving car is going to kill somebody or whatever. And let's say there's a political movement, the Luddites that is successful, and let's just say that every self-driving car in America is attacked and destroyed by mobs and that all of the companies that are making these cars are no longer able to produce or deploy those cars. That's going to be bad for self-driving cars in America — it's not going to be bad for self-driving cars. . . They're going to be developed in some other place. There are lots of societies that have lost their vitality. That's the story of every empire that we read about in history books: there was political corruption, sclerosis. That's very much an option.I'm a patriotic American and I hope America leads these revolutions as long as we can maintain our values for many, many centuries to come, but for that to happen, we need to invest in that. Part of that is investing now so that people don't feel that they are powerless victims of these trends they have no influence over.That's why all of my work is about engaging people in the conversation about how do we deploy these technologies? Because experts, scientists, even governments don't have any more authority to make these decisions about the future of our species than everybody else. What we need to do is have broad, inclusive conversations, engage people in all kinds of processes, including governance and political processes. That's why I write the books that I do. That's why I do podcast interviews like this. My Joe Rogan interviews have reached many tens of millions of people — I know you told me before that you're much bigger than Joe Rogan, so I imagine this interview will reach more than that.I'm quite aspirational.Yeah, but that's the name of the game. With my last book tour, in the same week I spoke to the top scientists at Lawrence Livermore National Laboratory and the seventh and eighth graders at the Solomon Schechter Hebrew Academy of New Jersey, and they asked essentially the exact same questions about the future of human genetic engineering. These are basic human questions that everybody can understand and everybody can and should play a role and have a voice in determining the big decisions and the future of our species.To what extent is the future you're talking about dependent on continued AI advances? If this is as good as it gets, does that change the outlook at all?One, there's no conceivable way that this is as good as it gets because even if the LLMs, large language models — it's not the last word on algorithms, there will be many other philosophies of algorithms, but let's just say that LLMs are the end of the road, that we've just figured out this one thing, and that's all we ever have. Just using the technologies that we have in more creative ways is going to unleash incredible progress. But it's certain that we will continue to have innovations across the field of computer science, in energy production, in algorithm development, in the ways that we have to generate and analyze massive data pools. So we don't need any more to have the revolution that's already started, but we will have more.Politics always, ultimately, can trump everything if we get it wrong. But even then, even if . . . let's just say that the United States becomes an authoritarian, totalitarian hellhole. One, there will be technological innovation like we're seeing now even in China, and two, these are decentralized technologies, so free people elsewhere — maybe it'll be Europe, maybe it'll be Africa or whatever — will deploy these technologies and use them. These are agnostic technologies. They don't have, as I said at the start, an inevitable outcome, and that's why the name of the game for us is to weave our best values into this journey.What is a “newnimal”? (30:11). . . we don't live in a state of nature, we live in a world that has been massively bio-engineered by our ancestors, and that's just the thing that we call life.When I was preparing for this interview and my research assistant was preparing, I said, “We have to have a question about bio-engineered new animals.” One, because I couldn't pronounce your name for these . . . newminals? So pronounce that name and tell me why we want these.It's a made up word, so you can pronounce it however you want. “Newnimals” is as good as anything.We already live in a world of bio-engineered animals. Go back 50,000 years, find me a dog, find me a corn that is recognizable, find me rice, find me wheat, find me a cow that looks remotely like the cow in your local dairy. We already live in that world, it's just people assume that our bioengineered world is some kind of state of nature. We already live in a world where the size of a broiler chicken has tripled over the last 70 years. What we have would have been unrecognizable to our grandparents.We are already genetically modifying animals through breeding, and now we're at the beginning of wanting to have whatever those same modifications are, whether it's producing more milk, producing more meat, living in hotter environments and not dying, or whatever it is that we're aiming for in these animals that we have for a very long time seen not as ends in themselves, but means to the alternate end of our consumption.We're now in the early stages xenotransplantation, modifying the hearts, and livers, and kidneys of pigs so they can be used for human transplantation. I met one of the women who has received — and seems to so far to be thriving — a genetically modified pig kidney. We have 110,000 people in the United States on the waiting list for transplant organs. I really want these people not just to survive, but to survive and thrive. That's another area we can grow.Right now . . . in the world, we slaughter about 93 billion land animals per year. We consume 200 million metric tons of fish. That's a lot of murder, that's a lot of risk of disease. It's a lot of deforestation and destruction of the oceans. We can already do this, but if and when we can grow bioidentical animal products at scale without having all of these negative externalities of whether it's climate change, environmental change, cruelty, deforestation, increased pandemic risk, what a wonderful thing to do!So we have these technologies and you mentioned that people are worried about them, but the reason people are worried about them is they're imagining that right now we live in some kind of unfettered state of nature and we're going to ruin it. But that's why I say we don't live in a state of nature, we live in a world that has been massively bio-engineered by our ancestors, and that's just the thing that we call life.Inspired by curiosity (33:42). . . the people who I love and most admire are the people who are just insatiably curious . . .What sort of forward thinkers, or futurists, or strategic thinkers of the past do you model yourself on, do you think are still worth reading, inspired you?Oh my God, so many, and the people who I love and most admire are the people who are just insatiably curious, who are saying, “I'm going to just look at the world, I'm going to collect data, and I know that everybody says X, but it may be true, it may not be true.” That is the entire history of science. That's Galileo, that's Charles Darwin, who just went around and said, “Hey, with an open mind, how am I going to look at the world and come up with theses?” And then he thought, “Oh s**t, this story that I'm coming up with for how life advances is fundamentally different from what everybody in my society believes and organizes their lives around.” Meaning, in my mind, that's the model, and there are so many people, and that's the great thing about being human.That's what's so exciting about this moment is that everybody has access to these super-empowered tools. We have eight billion humans, but about two billion of those people are just kind of locked out because of crappy education, and poor water sanitation, electricity. We're on the verge of having everybody who has a smartphone has the possibility of getting a world-class personalized education in their own language. How many new innovations will we have when little kids who were in slums in India, or in Pakistan, or in Nairobi, or wherever who have promise can educate themselves, and grow up and cure cancers, or invent new machines, or new algorithms. This is pretty exciting.The summary of the people from the past, they're kind of like the people in the present that I admire the most, are the people who are just insatiably curious and just learning, and now we have a real opportunity so that everybody can be their own Darwin.On sale everywhere The Conservative Futurist: How To Create the Sci-Fi World We Were PromisedMicro Reads▶ Economics* AI Hype Is Proving to Be a Solow's Paradox - Bberg Opinion* Trump Considers Naming Next Fed Chair Early in Bid to Undermine Powell - WSJ* Who Needs the G7? - PS* Advances in AI will boost productivity, living standards over time - Dallas Fed* Industrial Policy via Venture Capital - SSRN* Economic Sentiment and the Role of the Labor Market - St. Louis Fed▶ Business* AI valuations are verging on the unhinged - Economist* Nvidia shares hit record high on renewed AI optimism - FT* OpenAI, Microsoft Rift Hinges on How Smart AI Can Get - WSJ* Takeaways From Hard Fork's Interview With OpenAI's Sam Altman - NYT* Thatcher's legacy endures in Labour's industrial strategy - FT* Reddit vows to stay human to emerge a winner from artificial intelligence - FT▶ Policy/Politics* Anthropic destroyed millions of print books to build its AI models - Ars* Don't Let Silicon Valley Move Fast and Break Children's Minds - NYT Opinion* Is DOGE doomed to fail? Some experts are ready to call it. - Ars* The US is failing its green tech ‘Sputnik moment' - FT▶ AI/Digital* Future of Work with AI Agents: Auditing Automation and Augmentation Potential across the U.S. Workforce - Arxiv* Is the Fed Ready for an AI Economy? - WSJ Opinion* How Much Energy Does Your AI Prompt Use? I Went to a Data Center to Find Out. - WSJ* Meta Poaches Three OpenAI Researchers - WSJ* AI Agents Are Getting Better at Writing Code—and Hacking It as Well - Wired* Exploring the Capabilities of the Frontier Large Language Models for Nuclear Energy Research - Arxiv▶ Biotech/Health* Google's new AI will help researchers understand how our genes work - MIT* Does using ChatGPT change your brain activity? Study sparks debate - Nature* We cure cancer with genetic engineering but ban it on the farm. - ImmunoLogic* ChatGPT and OCD are a dangerous combo - Vox▶ Clean Energy/Climate* Is It Too Soon for Ocean-Based Carbon Credits? - Heatmap* The AI Boom Can Give Rooftop Solar a New Pitch - Bberg Opinion▶ Robotics/Drones/AVs* Tesla's Robotaxi Launch Shows Google's Waymo Is Worth More Than $45 Billion - WSJ* OpenExo: An open-source modular exoskeleton to augment human function - Science Robotics▶ Space/Transportation* Bezos and Blue Origin Try to Capitalize on Trump-Musk Split - WSJ* Giant asteroid could crash into moon in 2032, firing debris towards Earth - The Guardian▶ Up Wing/Down Wing* New Yorkers Vote to Make Their Housing Shortage Worse - WSJ* We Need More Millionaires and Billionaires in Latin America - Bberg Opinion▶ Substacks/Newsletters* Student visas are a critical pipeline for high-skilled, highly-paid talent - AgglomerationsState Power Without State Capacity - Breakthrough JournalFaster, Please! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Andrew Craig returns for his second appearance on the podcast, and in this episode, we delve into why so many people make investment mistakes—or choose not to invest at all. We also explore the UK's wealth crisis, discussing its causes and potential solutions. Andrew shares insights from his latest book Our Future Is Biotech, revealing the groundbreaking scientific advancements that could lead to healthier, longer lives.Join us as we discuss the role of financial literacy, the biotech revolution, and the power of compounding in creating lasting personal and financial growth.00:00 The UK's Wealth Crisis: An Overview00:25 The Biotech Revolution: A New Era01:06 The Cash ISA Dilemma01:45 The Impact of Financial Journalism03:37 The Economic Consequences of Poor Investment06:57 The Global Wealth Disparity13:31 The Role of Technology in Wealth Creation19:56 The Importance of Financial Literacy32:45 Healthy Eating Habits from Childhood33:20 Economic Growth and Wealth Creation34:46 Reflecting on the 1970s Economy36:54 The Future of Biotech47:44 Gene Editing and CRISPR Technology52:08 The Rise of Autism and ADHD58:45 The Complexity of Human Biology01:04:55 Discussing Chris Hemsworth and Free Solo01:05:09 The Importance of Visualization in Extreme Sports01:05:43 Pushing the Frontiers of Human Capability01:06:53 The Power of Compounding and Consistency01:08:49 Exciting Advances in Microbiome and Bioremediation01:10:05 The Miracles of Precision Medicine01:12:49 The Abundance of Modern Life01:15:40 The Importance of Reading and Continuous Learning01:18:49 The Impact of Podcasts on Personal Growth01:22:29 Economic Models and Government Intervention01:26:58 Concluding Thoughts and ReflectionsDiscover AndrewWebsite - https://plainenglishfinance.co.uk/YouTube - https://www.youtube.com/channel/UCME6xVzdcA7q_RfhRaRIkPALinkedIn - https://www.linkedin.com/in/andrewcraigpef/?originalSubdomain=ukBooks - https://plainenglishfinance.co.uk/booksGet In TouchLinkedIn - www.linkedin.com/in/jay-lawrence-5a4b3357/Website - ambitiousmindspodcast.comInstagram - www.instagram.com/ambitiousmindspodcast Hosted on Acast. See acast.com/privacy for more information.

durée : 00:58:04 - Avec philosophie - par : Géraldine Muhlmann, Nassim El Kabli - On croit savoir ce que sont les nouvelles technologies NBIC (Nanotechnologies, Biotechnologies, sciences de l'Information et de la Cognition). On entend là-dedans des progrès possibles, pour la médecine par exemple, mais on se doute aussi qu'il y a des risques. Se posent donc des enjeux éthiques. - réalisation : Nicolas Berger - invités : Vanessa Nurock Philosophe, maître de conférences en théorie politique et éthique à l'université Paris 8; François Berger Neuroscientifique, directeur de l'unité INSERM BrainTech Lab, qui développe les technologies innovantes pour comprendre et traiter les pathologies cérébrales.

Founded in 2017 and headquartered in Singapore, MO MAYA began with a mission to create luxurious, handcrafted pieces as beautiful as they are sustainable. After graduating from Georgetown University and getting a degree in Biotechnology, Parul Jain was led to develop MO MAYA when she could not find affordable, hand-made luxurious pieces in Singapore. MO MAYA takes pride in being sustainable, with an emphasis on style. Shop at itsmomaya.com 

What does it look like to take a neuroscience degree far beyond the lab? In this episode, we explore a career path that crosses scientific research, government regulation, and biotech entrepreneurship with Dr. Amanda Wiggins, CEO of The cGP Lab. Amanda began her career investigating neurodegeneration and cortical spreading depression. Over time, her passion for real-world impact led her into public policy—where she helped shape New Zealand's Human Tissue Act and advised on regulations for stem cell research and genetic technologies. Today, she leads a company advancing neuroprotective health supplements based on cyclic Glycine-Proline (cGP), a molecule with growing potential in aging and cognitive health. We talk about: How to navigate transitions between academia, government, and business The challenges of working across disciplines—and how to build confidence in new spaces Lessons learned from leading regulatory change and scaling innovation Amanda's work at The cGP Lab and the science behind cGP's potential in brain health Advice for scientists who want to move into leadership, entrepreneurship, or public engagement This conversation is for anyone considering a non-linear career in neuroscience or wondering how to apply scientific training in new and meaningful ways. Chapters: 00:00:02 - Bridging Neuroscience and Biotech Innovation 00:04:06 - FDA Approval of Trofinetide for Rett Syndrome 00:07:27 - My Journey in Science and Identity 00:09:22 - Pursuing a PhD in Melbourne 00:11:55 - Choosing a PhD Topic 00:17:26 - Challenges and Motivation in PhD Journey 00:20:54 - Transition from Academia to Regulatory Work 00:22:52 - Transitioning from Academia to Policy 00:25:51 - Advising on the Human Tissue Act 00:29:18 - Advocating Biotechnology in New Zealand 00:33:51 - Regulations and Challenges in Biotechnology 00:37:49 - Newborn Blood Screening and Research Ethics 00:41:22 - Transitioning from Science to Biotech 00:46:04 - Challenges of Startup Success 00:48:34 - Journey to Neuroactive Innovation 00:55:23 - Mentorship and Startup Advice 00:58:49 - Dementia Prevention and Early Detection 01:02:03 - Exploring Alzheimer's Research Frontiers 01:06:45 - Advancing Your Neurocareer About the Podcast Guest:

In this episode of the 'In the Woods' podcast from Oregon State University's Forestry and Natural Resources Extension Program, host Scott Leavengood & Guest host from OSU's BIOTECH Insight's podcast BioTech Talks, discusses forest biotechnology with Dr. Steve Strauss. Dr. Strauss, a professor of forest biotechnology at OSU, shares insights from his 40-year career, including the genetic engineering of trees, the use of Agrobacterium for DNA modification, and the challenges and opportunities in the field. They also address public misconceptions about genetic engineering and its potential to address climate change. The episode concludes with a lightning round of questions about Dr. Strauss's favorite tree species and the impact of CRISPR technology.

I. Glenn Cohen is a professor of law and deputy dean at Harvard Law School and faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. I.G. Cohen, I. Ajunwa, and R.B. Parikh. Medical AI and Clinician Surveillance — The Risk of Becoming Quantified Workers. N Engl J Med 2025;392:2289-2291.

Welcome to The Plaidchat- an extension of The Plaidcast where we expand upon conversations in our sport and discuss the most recent issue of The Plaid Horse Magazine. Piper speaks with TPH Small business winner, Caitlin Looney of Extend Equine Massage. Listen in and share with friends!Host: Piper Klemm, publisher of The Plaid HorseGuest: Caitlin Looney is a certified equine bodyworker and owns Extend Equine Massage, which services the Massachusetts and New Hampshire areas offering equine massage, kinesiology taping, red light therapy and more! Holding her Masters in Biotechnology, Caitlin brings a unique scientific understanding of the horse's muscular system to her practice to provide reproducible and significant results. Riding at such diverse levels herself ranging from 4H to the breed level, Caitlin appreciates all aspects of competition and enjoys supporting a wide array of clients from the retired pony to the high performing equine athlete.Read the Latest Issue of The Plaid Horse MagazineSubscribe To: The Plaid Horse MagazineTitle Sponsor: Taylor, Harris Insurance ServicesSponsors: Taylor, Harris Insurance Services, BoneKare and Great American Insurance Group Join us at an upcoming Plaidcast in Person event!

Join Vonnie Estes as she hosts a captivating discussion with Karen Carr on the evolving landscape of agricultural biotechnology. Delve into the regulatory challenges and opportunities surrounding gene editing, with insights into developments in the US and EU. Discover how these technologies could impact agricultural practices, consumer choice, and public health. Karen shares her expertise on navigating complex regulatory frameworks and the role of NGOs, while exploring the promising future of breeding technologies that enhance nutrition and sustainability. Don't miss this deep dive into the future of food and agriculture innovation.Key TakeawaysUSDA's Product-Based Regulation: The U.S. regulatory framework prioritizes evaluating the safety of the end products rather than focusing solely on the breeding processes.Implications of the December Court Decision: A pivotal court ruling in December 2024 mandates USDA to revert to older regulations, impacting gene-edited crops and regulatory procedures.Role of NGOs: NGOs can influence policy and public perception, often leading to reduced consumer and producer choices in the biotechnology space.International Regulatory Trends: Promising developments in EU regulatory practices for gene editing could reshape global agricultural biotechnology.Efficiency in Regulation: The focus remains on streamlining regulations to support innovation, ensuring efficient and clear pathways for commercializing new technologies.Guest ResourcesArentFox Schiff: https://www.afslaw.com/ [A global law firm where Karen leads the Ag Technology Regulatory Practice Group]USDA's Regulatory Framework: https://www.aphis.usda.gov/ International Fresh Produce Association: https://www.freshproduce.com/ Join the conversation and gain deeper insights by listening to the full episode. Stay tuned for more groundbreaking discussions on innovation in agriculture and food through “Fresh Takes on Tech.”Show LinksInternational Fresh Produce Association - https://www.freshproduce.com/Fresh Takes on Tech - https://www.freshproduce.com/resources/technology/takes-on-tech-podcast/Facebook - https://www.facebook.com/InternationalFreshProduceAssociation/Twitter - https://twitter.com/IntFreshProduce/LinkedIn - https://www.linkedin.com/company/international-fresh-produce-association/Instagram - https://www.instagram.com/intlfreshproduceassn/

The podcast edition of Charlottesville Community Engagement marks the end of the workweek for the devoted staff at Town Crier Productions and the beginning of the next one. The mission is to write as much as possible and to always strive to capture more. The podcast edition reaches about a tenth of the audience for the written version. From a production standpoint, they're the same thing - stories about the community that may help you understand some of the shifting dynamics. I'm Sean Tubbs, and I'm glad to be able to bring this information to you.On this edition:* Inaugural director of Manning Institute of Biotechnology shares vision with UVA Board (learn more)* UVA surpasses $6 billion in major fundraising campaign (learn more)* Charlottesville Planning Commission briefed on forthcoming updates to zoning code (learn more)* UVA provides update on construction projects to Charlottesville Planning Commission (learn more)* City parks and recreation put garden plot term limits on hold (learn more)* Albemarle County Supervisors get briefings on the cost of county services as well as economic development (stories come out on Monday)Charlottesville Community Engagement is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Soul-searching SaturdayThere are no shout-outs in the print edition but I'll take this Saturday afternoon to write up the current state of that form of public announcements. I've strived to be transparent with how my company makes revenue.Prior to launching this newsletter on July 13, 2020, I launched a Patreon account for people who wanted to provide seed money for the overall venture. I did not know how I would distribute the work. At the time, my work consisted of a podcast called the Charlottesville Quarantine Report.That went out through Simplecast, and I still pay $15 a month to host the work until I can figure out a more permanent place for it to live. I think it is a valuable archive of a time in history. If you want to hear one, go back and listen to the June 8, 2020 edition which gave an update on what local government was doing.Producing that program made me want to move forward with this newsletter, which was a podcast for almost all of the first 700 editions. These were very short in nature at first but expanded over time as I got used to doing the work.If you look at the print version of the July 13, 2020 edition, there is no shout-out. There are also no pictures. No headlines. It's literally a radio script. If you take a listen, you'll hear a shout-out to Rapture. I put that in as a placeholder as I spent some time in public radio and wanted to do something. At the time, the place had reopened under COVID rules and it was where I spent time away from home.In the July 15, 2020 edition, I noted that Mead Oriental Rugs was supporting the show in both the print and the written versions. I'm friends with the owner. There was no money exchanged.In the fourth version, College Inn was a shout-out. One of the owners let me do this and I don't remember if we had any sort of an arrangement or not. They're now gone.This continued for those first few weeks with me adding in others here and there, even promoting the Charlottesville Podcasting Network. That's the site I created in 2005 as an experiment in audio distribution.By the 14th edition of the newsletter, I began to implement something from the Patreon world. For most of the time of the site, if you paid $25 a month through Patreon, you'd get a certain number of “shout-outs” in the newsletter. I began to track these, as there were many people willing to support the work.And so on. Now we're up to 879 editions of the regular newsletter, and over 315 editions of the Week Ahead newsletter. All produced by one person. However, the business has grown incrementally, and there is now much in the shout-out system that needs to be fixed.I'm hoping to do that over the course of the year. I'm no longer taking any new requests under the old system but I have two paid advertisers who are going to work with me as I begin to put the new system in place. This will be a mixture of message here in Substack, banner ads on Information Charlottesville, as well as mentions in the podcast.The shout-out will continue and the new policy will contain some way of getting public service announcements. There are thousands of you reading this newsletter and I suspect that number will grow as more people learn.Now I need to get going because the next set of stories beckon. Thank you for reading to this point if you did. If you didn't read to this point, please know I'm waving at you and saying hello anyway.Thanks for reading Charlottesville Community Engagement ! This post is public so feel free to share it. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit communityengagement.substack.com/subscribe

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoices

Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of that figure. Not surprising when you think that healthcare focused biotech companies are battling to solve some of our biggest health concerns; turning an ageing society into a longevity society by supporting longer and healthier lives. In this episode of The Next Five, Paul Little, CEO of Vesper Bio discusses frontotemporal dementia and the impact of it on human health and society, the biotech solutions being sort to combat the disease as well as what he describes as a Malthusian crisis around biotech funding. Dr Ann Beliën, Founder and CEO of Rejuvenate Biomed addresses the problems of Sarcopenia as well as the biotech solutions for it and how Biotech companies use creative ways to secure funding. Gianmario Verona, President of Human Technopole, highlights the importance of industry collaboration and how innovation centres can help propel the biotech sector forward. Sources: FT Resources, WHO, JP Morgan, Alzheimersresearchuk, IQVIA This content is paid for by Yes Milano and is produced in partnership with the Financial Times' Commercial Department. Hosted on Acast. See acast.com/privacy for more information.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Phytoremediation. A fun word to say, but what does it mean? Turns out it's quite simple: using the superpower many plants naturally have to heal our wonderful Earth from terrible soil contaminants. Allan pulls us off the dark abyss edge that is our current world to deliver a wonderful tale of plants. Primary Sources: Gerhardt KE, Gerwing PD, Greenberg BM. Opinion: Taking phytoremediation from proven technology to accepted practice. Plant Sci. 2017 Mar;256:170-185. Epub 2016 Dec 5. PMID: 28167031. Lee, Jae. (2013). An overview of phytoremediation as a potentially promising technology for environmental pollution control. Biotechnology and Bioprocess Engineering. 18. +++ More of Our Work +++ Website Facebook TikTok Twitch Bluesky +++ Contact Us +++ Text/Call: (316)-512-8933 info@grasslandgroupies.org +++ Support Us +++ Bonfire Merch Store CashApp: $GrasslandGroupies Or... donate directly to our org.

In this episode, we sit down with Dr. Mark Esser, the inaugural Chief Scientific Officer of UVA's new Paul and Diane Manning Institute of Biotechnology. Dr. Esser, a renowned expert in immunology and vaccine development, shares his journey from AstraZeneca to leading this ambitious institute. With a vision to revolutionize healthcare and accelerate the development of life-saving treatments, Mark discusses fostering innovation, attracting biotech companies to Virginia, and the future of personalized medicine.

Biotechnology company 23andMe is being taken to court by over 27 US states over plans to auction off customers' personal genetic information without their consent. The company has collected biological samples and genetic information from over 15 million customers - including many here in New Zealand. Privacy lawyer Rick Shera says 23andMe's built a tempting service - but you never know where this stuff will end up. "We don't know what they're going to do with it, and that's the problem. Terms of service and privacy policies can be changed almost willy-nilly these days." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Tonight on The Huddle, Jack Tame from ZB's Saturday Mornings and Q&A and Jordan Williams from the Taxpayers' Union joined in on a discussion about the following issues of the day - and more! Groundswell is calling on the Government to pull New Zealand out of the Paris Agreement. Do we see ourselves leaving - or will the agreement fall apart on its own? Biotechnology company 23andMe is being taken to court by multiple US states over plans to auction off customers' personal genetic information without their consent. Have we ever done one of these tests? What would happen if this data got sold? LISTEN ABOVESee omnystudio.com/listener for privacy information.

In this episode of Speaking of Mol Bio, Dr. Cath Moore of the Australian Genome Research Facility (AGRF) discusses how molecular biology technologies are helping to shape Australia's scientific landscape—from clinical genomics and conservation to bioremediation and agriculture. With over 20 years of experience in both academia and industry, Dr. Moore reflects on the remarkable evolution of genomic tools, from Sanger sequencing to high-resolution spatial multiomics.She unpacks AGRF's mission to democratize access to emerging technologies and highlights its role as an early adopter of platforms that help scientists translate academic research into real-world impact. Topics include non-mass spec proteomics, mine site rehabilitation through soil microbiome analysis, and the role of systems biology in modern science.Dr. Moore also discusses the importance of community education and literacy around genomics, emphasizing how public understanding is key to the safe adoption of emerging technologies like synthetic biology. Finally, she shares career insights and advice for aspiring scientists: stay curious, stay broad, and don't be afraid to pivot when your work no longer brings joy. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of the Fitness + Technology Podcast, Bryan O'Rourke shares his keynote, “The Key Trends Creating Opportunities and Challenges for the Global Fitness Industry in the Next 5 Years” live from Beyond Activ in Singapore. Bryan shares the spotlight for what's next for fitness across the globe — from emerging technologies and programming innovations to finance, business models, and the forces reshaping how to serve members and scale impact. Whether you lead a gym, studio, supplier brand, or digital platform, this talk is designed to challenge your thinking and equip you for what's ahead. To view the slideshow, go to: https://www.slideshare.net/slideshow/future-of-fitness-2025-keynote-bryan-orourke-beyond-activ-singapore-2025/280332550 One Powerful Quote: 7:41: “In a world deluged by irrelevant information, clarity is power.” 4-10 Bullet Points (w/ timestamps) - Highlighting key topics discussed: 3:09: Bryan opens his keynote with “What if?” and the convergence of macro/micro trends.  7:47: Bryan talks about opportunities and challenges in the next 5 years.  11:31: Bryan articulates on business models as the mainstay configurations for fitness delivery.  15:40: Bryan speaks on biotechnologies and the new social constructs today.  17:40: Bryan defines leadership vision and the processes to execute on it.  19:09: Bryan recaps his presentation.  Bullet List of Resources: https://beyondactiv.com/ Guest Contact Information: https://www.bryankorourke.com/ https://www.linkedin.com/in/bryankorourke/ http://www.fittechcouncil.org/ https://www.youtube.com/user/bko61163

Explore the science behind genetically engineered probiotics with Zack Abbott, PhD of ZBiotics. We talk about hacking gut bacteria to reduce hangovers and turn sugar into fiber—plus why bacterial diversity is key to better health. Lindsey Parsons, your host, helps clients solve gut issues and reverse autoimmune disease naturally. Take her quiz to see which stool or functional medicine test will help you find out what's wrong. She's a Certified Health Coach at High Desert Health in Tucson, Arizona. She coaches clients locally and nationwide. You can also follow Lindsey on Facebook, Tiktok, X, Instagram or Pinterest or reach her via email at lindsey@highdeserthealthcoaching.com to set up your free 30-minute Gut Healing Breakthrough Session. Show Notes

In 2019, a study from Denmark by Hviid, et al, purported to demonstrate that there was no link between the MMR vaccine and autism, even among genetically susceptible populations.The study was strongly critiqued at the time, and now, journalist Jeremy R. Hammond, along with Dr. Brian Hooker and Dr. Jeet Varia, has published a paper that addresses the serious flaws in Hviid et al, in the Journal of Biotechnology and Biomedicine. I talk with Jeremy about Hviid et al, and about his own paper, and about the state of research into the connection between vaccines and autism more broadly.Links:Hviid et al. 2019Jeremy's paperThis article summarizes key points from Jeremy's paper:I discussed medical licensing with Jeremy here.Jeremy exposes the WaPo's Lena Sun here....and the AAP's “vaccines do not cause autism” claim, here.Jeremy's book, "The War on Informed Consent" is one of the most concise and informative works on the suppression of science and discussion regarding vaccines.https://www.jeremyrhammond.com/product/the-war-on-informed-consent/You can find Jeremy here, and here. 

Our guest this week, Lara Campana is SVP of Research & Translational Science and a co-founder of Resolution Therapeutics, a company developing regenerative macrophage therapies for inflammatory and fibrotic diseases. In this episode of Careers in Discovery, Lara shares her journey from medical Biotechnology student in Milan to Biotech executive in the UK, and why she's been fascinated by macrophages ever since a single line in a university lecture hinted at their regenerative potential. We talk about the origins of Resolution, how the company grew from a trio of postdocs in a university lab to a clinical-stage Biotech, and the challenges of leading teams, building culture, and letting go as a founder. Lara also reflects on the mindset shift from academic research to pragmatic, patient-focused drug development - and the lessons she's learned along the way about influence, resilience, and finding space to think.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron's shares have dropped due to the failure of their dupixent follow-up drug, while Sanofi has acquired Blueprint for $9.5 billion to expand their rare disease portfolio. Bristol Myers Squibb is collaborating with Biontech on a bispecific antibody for solid tumors, and Amgen's imdelltra has shown a 40% increase in survival for small cell lung cancer at ASCO. Moderna has received FDA approval for their next-gen COVID-19 vaccine, and AstraZeneca is partnering with AI companies to stop cancer at all stages. Keros has cut 45% of its workforce along with a pulmonary hypertension drug, and Jazz has presented new cancer data at ASCO. FDA actions are pending for companies like Merck, Gilead, and Regeneron/Sanofi.The implications of the overturning of the FDA's lab-developed tests rule in a post-Chevron legal landscape are discussed, where power has shifted from federal agencies to the courts. Upcoming FDA decisions, including Gilead's HIV prophylaxis lenacapavir, are highlighted, along with new FDA guidelines on nitrosamine testing for the pharmaceutical industry. Jazz Pharmaceuticals is in the "goldilocks zone" with new cancer data at ASCO25, showcasing results from acquisitions made over the past five years. Zeiss introduces an AI-powered spatial biology solution for research labs. Other news includes updates from ASCO25, cell and gene therapy developments, and upcoming events in the biopharma industry.

Can science turn any blood into a universal donor type? Join us in this episode as we explore groundbreaking healthcare innovations with Maher Abou Hachem, a distinguished Professor in the Department of Biotechnology and Biomedicine at the Technical University of Denmark. Maher's expertise spans recombinant protein production, purification, biomolecular interactions, stability, and enzymology. From gut microbiome studies to pioneering blood type conversion, his cutting-edge research is reshaping the future of healthcare. Are you ready to find out what makes Maher's work so unique? Hit play to find out! Dive in now to discover: What the major blood types are, and how they are used in transfusion and transplant applications. What happens if you give the wrong blood type to a patient. How researchers can change one blood type to another. The significance of red blood cells in the human body. You can learn more about Maher and his investigations here! Episode also available on Apple Podcasts: http://apple.co/30PvU9

Art Bell - Michael Fumento - Biotechnology Developments

In this episode we are exploring two publications related to cancer care. In our first segment we talk to 2 authors about their research on genetic counselors and identification of patients for high-risk pancreatic cancer screening. In our second segment, Khalida interviews a genetic counselor about their study to evaluate surgical patient perspectives of genetic testing provided by a non-genetics professional.  Segment 1: “Practices and perspectives of genetic counselors about high-risk pancreatic cancer screening: A cross-sectional survey study” Amy Wiegand is a board-certified genetic counselor who specializes in cancer genetics. She graduated with her Master's in Genetic Counseling in 2017 from from the Icahn School of Medicine at Mount Sinai and has worked as a cancer genetic counselor at the Smilow Cancer Genetics and Prevention Program at Yale-New Haven Health since 2017 where she has seen over 2500 patients for a variety of hereditary cancer indications. Her research interests include hereditary pancreatic cancer and alternative delivery care models for genetic testing. Aparna is a senior genetic counseling assistant (GCA) at Smilow Cancer Genetics and Prevention Program at Yale New Haven Health where she has worked since 2019, and she has over 6 years of experience as a GCA. She holds a Master's degree in Biomedical Genetics and a Bachelor's degree in Biotechnology. She also has a varied background in administration, finance and customer service. She is a high-performing individual and was recently recognized by her colleagues as ‘Employee of the Quarter' and honored by the organization as ‘Smilow Star' for consistently going above and beyond for the patients and the co-workers and for exemplifying the health system's values. She contributes to the program in a variety of other ways outside of her role and works collaboratively with the team to create a patient centered environment. She has a strong interest in Cancer Genetics and is passionate about research. She is currently working on another research project, the abstract of which was selected for presentation in a Poster Session at 2025 ASCO (American Society of Clinical Oncology) annual meeting. She enjoys being part of a collaborative and dynamic team at Smilow Cancer Genetics and Prevention program and is excited about the upcoming research initiatives in the program. In this segment we discuss: - The significance of pancreatic cancer surveillance for high-risk individuals and why early detection plays a critical role in improving outcomes. - How genetic counselors are uniquely positioned to identify and refer individuals at high risk for pancreatic cancer, emphasizing their role in screening efforts. - An overview of the 2019 CAPS (Cancer of the Pancreas Screening) consensus guidelines and how they are applied to identify high-risk individuals for surveillance - The finding that nearly 70% of genetic counselors accurately identified individuals eligible for screening and discussed the factors that may have contributed to this high rate. - The association between provider comfort level and accuracy in identifying high-risk individuals, and discussed strategies to improve provider confidence and access to screening programs.   Segment 2: “Patient experiences of cancer genetic testing by non-genetics providers in the surgical setting” Katie Fiallos is a board-certified genetic counselor who earned her Master of Science in Genetic Counseling from the Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training program in 2017 and worked for seven years as a cancer genetic counselor at Johns Hopkins. She joined the Department of Medical and Molecular Genetics at Indiana University in August 2024. She is fluent in Spanish and provides genetic counseling in English and Spanish to participants with Parkinson's disease enrolled in the PD GENEration study. She has authored several academic papers related to genetic counseling, and her current research interests include provision of genetic counseling to Latine individuals, alternate service delivery models, and patient experiences with genetic testing and their informational desires. She lives in Michigan with her family and enjoys staying active, particularly practicing aerial silks. The research for the paper we're discussing was done while she was at Johns Hopkins and was funded by the Jennifer L. Brager Memorial Research award through the Johns Hopkins Kimmel Cancer Center.   In this segment we discuss: - Why hereditary cancer genetic testing is becoming increasingly important for patients with breast cancer, especially in relation to surgical decision-making. - The findings that patients preferred genetic testing at an existing appointment shortly after diagnosis, and explored how this timing affects their overall experience. - How many patients had already considered or wanted genetic testing before it was offered, shedding light on patient awareness and readiness. - Why patients were primarily motivated by concern for relatives and a desire for complete information, rather than surgical decision-making. - Gaps in patient-provider communication identified in the study and suggested ways for providers to address these issues in clinical practice.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Send us a textEpisode Summary: Dr. Andrew Chadeayne discusses the chemistry of psilocybin and other psychedelics, their potential therapeutic applications, and the challenges of commercializing them in a shifting biotech market. The conversation delves into the complexities of magic mushroom composition, debunking myths like "lemon tekking," and uncovers the booming, unregulated alternative products industry, including kratom and synthetic psilocybin analogs sold in vape shops.About the guest: Andrew Chadeayne, PhD is a chemist who also holds a law degree, specializing in patent law. He is the founder and CEO of CaaMTech, a startup specializing in the development of novel psychedelic compounds. Chadeayne collaborates with academic labs to advance psychedelic science while navigating the commercial landscape.Discussion Points:Psilocybin is a prodrug converted to psilocin, but magic mushrooms contain other psychoactive molecules like beta-carbolines, which may enhance effects by inhibiting degradation.Chadeayne's team develops psilocin prodrugs to shorten psychedelic trips, making clinical administration more manageable without altering effects.The "lemon tek" myth—that lemon juice converts psilocybin to psilocin—is false; it enhances absorption by extracting compounds, not altering chemistry.Magic mushroom bruising indicates psilocin degradation, as oxidized psilocin forms blue, inactive dimers.The multi-billion dollar alternative products industry sells kratom and synthetic psilocybin analogs, often mislabeled, in vape shops, raising safety and regulatory concerns.Kratom's minor alkaloid, 7-hydroxymitragynine, is ~40x more potent than morphine, with no reported overdoses but high habit-forming potential.Non-hallucinogenic serotonin 2A agonists, like those developed by CaaMTech's spinout, show promise for conditions like migraines without requiring a psychedelic trip.Related episode:M&M 71: Chemistry of Magic Mushrooms, DMT Analogues, Entourage Effects in Cannabis & Fungi, Novel Psychedelic Medicines, Psychedelic Startups | Andrew Chadeayne*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

Mariano Mattei is the Vice President of Cybersecurity and AI at Azzur Solutions, bringing over 30 years of expertise in cybersecurity, AI innovation, and software engineering. A Certified Chief Information Security Officer (CCISO), Mariano has led AI-driven transformations across Biotechnology, Pharmaceuticals, and Medical Device sectors, integrating AI into clinical trials, manufacturing automation, quality systems, and regulatory compliance frameworks (FDA 21 CFR Part 11, GAMP 5, GDPR, HIPAA). His work spans predictive analytics for risk management, AI-powered process optimization, anomaly detection in manufacturing, and regulatory AI governance. He recently graduated from Temple University's Master's Program in Cyber Defense and Information Assurance, and he's the author of "Data-Driven Cybersecurity – Proven Metrics for Reducing Cyber Risk"Listen NOW to discover, "The Secret to Taking A Secure Risk"

This lecture is entitled Quandaries of Biotechnology: Theory and Practice - Session 2. It was presented by Lesley Rice of the Pontifical John Paul II Institute and Silvianne Aspray of Cambridge University on March 22, 2024, at the University of Chicago.